Digital diabetes care company Glooko announced today that its Mobile Insulin Dosing System (MIDS) — an app-driven tool that recommends insulin dose adjustments using data collected directly from a patient’s blood glucose meter — has been cleared by the FDA.
The MIDS module allows clinicians to create a customized treatment plan and send it to Type 2 diabetes patients directly through the company’...
